Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions
ARQT Stock Forecast
Arcutis Biotherapeutics stock forecast is as follows: an average price target of $31.00 (represents a 202.73% upside from ARQT’s last price of $10.24) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ARQT Price Target
The average price target for Arcutis Biotherapeutics (ARQT) is $31.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $18.00. This represents a potential 202.73% upside from ARQT's last price of $10.24.
ARQT Analyst Ratings
According to 4 Wall Street analysts, Arcutis Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ARQT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 0 'Hold' (0.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
Arcutis Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 15, 2024 | Serge Belanger | Needham | - | - | 121.40% | 75.78% |
| May 15, 2024 | Uy Ear | Mizuho Securities | - | - | 121.40% | 75.78% |
| Jan 02, 2024 | Mizuho Securities | - | - | 133.24% | -21.88% | |
| Dec 13, 2022 | Morgan Stanley | - | - | 207.60% | 398.05% | |
| Apr 27, 2022 | Eric Cha | Goldman Sachs | - | - | 88.63% | 261.33% |
The latest Arcutis Biotherapeutics stock forecast, released on May 15, 2024 by Serge Belanger from Needham, set a price target of $18.00, which represents a 121.40% increase from the stock price at the time of the forecast ($8.13), and a 75.78% increase from ARQT last price ($10.24).
Arcutis Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $14.67 |
| Last Closing Price | $10.24 | $10.24 | $10.24 |
| Upside/Downside | -100.00% | -100.00% | 43.26% |
In the current month, the average price target of Arcutis Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcutis Biotherapeutics's last price of $10.24. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Needham | Buy | Buy | Hold |
| Aug 28, 2024 | Jefferies | Underperform | Underperform | Hold |
| Aug 28, 2024 | Jefferies | Buy | Initialise | |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 10, 2024 | Needham | Buy | Buy | Hold |
| May 15, 2024 | Needham | Buy | Buy | Hold |
| Apr 12, 2024 | Needham | Buy | Buy | Hold |
| Apr 12, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
| Dec 13, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Apr 26, 2022 | Zacks Investment Research | Sell | Downgrade |
Arcutis Biotherapeutics's last stock rating was published by Needham on Aug 28, 2024. The company gave ARQT a "Buy" rating, the same as its previous rate.
Arcutis Biotherapeutics Financial Forecast
Arcutis Biotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $13.53M | $38.11M | $5.19M | $2.78M | $2.96M | $725.00K |
| Avg Forecast | $92.00M | $72.64M | $64.05M | $56.26M | $54.72M | $37.62M | $29.09M | $15.18M | $11.41M | $32.91M | $4.60M | $3.14M | $614.29K | $614.29K |
| High Forecast | $95.28M | $75.23M | $66.33M | $57.53M | $55.59M | $38.96M | $29.09M | $15.72M | $11.82M | $34.09M | $4.76M | $3.25M | $636.21K | $614.29K |
| Low Forecast | $89.35M | $70.55M | $62.20M | $55.00M | $53.84M | $36.53M | $29.09M | $14.74M | $11.08M | $31.97M | $4.47M | $3.05M | $596.59K | $614.29K |
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.19% | 1.16% | 1.13% | 0.89% | 4.82% | 1.18% |
Arcutis Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $15.18M, with a low forecast of $14.74M, and a high forecast of $15.72M. ARQT's average Quarter revenue forecast represents a 12.19% increase compared to the company's last Quarter revenue of $13.53M (Dec 23).
Arcutis Biotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-60.78M | $-34.18M | $-66.76M | $-73.06M | $-65.10M | $-102.53M |
| Avg Forecast | $18.40M | $14.53M | $12.81M | $11.25M | $10.94M | $7.52M | $5.82M | $3.03M | $2.28M | $6.58M | $919.68K | $627.50K | $122.86K | $122.86K |
| High Forecast | $19.06M | $15.05M | $13.27M | $11.51M | $11.12M | $7.79M | $5.82M | $3.14M | $2.36M | $6.82M | $952.50K | $649.89K | $127.24K | $122.86K |
| Low Forecast | $17.87M | $14.11M | $12.44M | $11.00M | $10.77M | $7.31M | $5.82M | $2.95M | $2.22M | $6.39M | $893.20K | $609.43K | $119.32K | $122.86K |
| Surprise % | - | - | - | - | - | - | - | - | -26.64% | -5.19% | -72.59% | -116.43% | -529.92% | -834.53% |
undefined analysts predict ARQT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Arcutis Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Arcutis Biotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-66.28M | $-44.77M | $-70.99M | $-79.74M | $-75.61M | $-110.67M |
| Avg Forecast | $-31.08M | $-29.21M | $-34.80M | $-41.64M | $-35.05M | $-51.85M | $-64.20M | $-85.15M | $-97.22M | $-113.58M | $-155.39M | $-159.69M | $-215.20M | $-213.78M |
| High Forecast | $-29.91M | $-28.12M | $-33.50M | $-37.29M | $-27.54M | $-49.91M | $-61.80M | $-81.96M | $-71.79M | $-109.33M | $-149.58M | $-153.71M | $-207.14M | $-213.78M |
| Low Forecast | $-32.52M | $-30.57M | $-36.42M | $-45.99M | $-40.06M | $-54.26M | $-67.18M | $-89.10M | $-121.15M | $-118.85M | $-162.60M | $-167.09M | $-225.18M | $-213.78M |
| Surprise % | - | - | - | - | - | - | - | - | 0.68% | 0.39% | 0.46% | 0.50% | 0.35% | 0.52% |
Arcutis Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ARQT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Arcutis Biotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $48.48M | $47.59M | $45.96M | $42.92M | $37.02M | $35.47M |
| Avg Forecast | $721.98M | $570.05M | $502.63M | $441.53M | $429.38M | $295.20M | $228.28M | $119.09M | $89.53M | $258.30M | $36.09M | $24.62M | $4.82M | $4.82M |
| High Forecast | $747.74M | $590.40M | $520.57M | $451.45M | $436.24M | $305.74M | $228.28M | $123.34M | $92.72M | $267.52M | $37.37M | $25.50M | $4.99M | $4.82M |
| Low Forecast | $701.19M | $553.64M | $488.16M | $431.62M | $422.52M | $286.70M | $228.28M | $115.66M | $86.95M | $250.86M | $35.05M | $23.91M | $4.68M | $4.82M |
| Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.18% | 1.27% | 1.74% | 7.68% | 7.36% |
Arcutis Biotherapeutics's average Quarter SG&A projection for Mar 24 is $119.09M, based on 1 Wall Street analysts, with a range of $115.66M to $123.34M. The forecast indicates a 145.66% rise compared to ARQT last annual SG&A of $48.48M (Dec 23).
Arcutis Biotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.72 | $-0.73 | $-1.16 | $-1.30 | $-1.24 | $-1.94 |
| Avg Forecast | $-0.25 | $-0.23 | $-0.28 | $-0.34 | $-0.28 | $-0.42 | $-0.52 | $-0.69 | $-0.78 | $-0.91 | $-1.25 | $-1.28 | $-1.73 | $-1.73 |
| High Forecast | $-0.24 | $-0.23 | $-0.27 | $-0.30 | $-0.22 | $-0.40 | $-0.50 | $-0.66 | $-0.58 | $-0.88 | $-1.20 | $-1.24 | $-1.67 | $-1.73 |
| Low Forecast | $-0.26 | $-0.25 | $-0.29 | $-0.37 | $-0.32 | $-0.44 | $-0.54 | $-0.72 | $-0.97 | $-0.96 | $-1.31 | $-1.34 | $-1.81 | $-1.73 |
| Surprise % | - | - | - | - | - | - | - | - | 0.92% | 0.80% | 0.93% | 1.01% | 0.72% | 1.12% |
According to undefined Wall Street analysts, Arcutis Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ARQT previous annual EPS of $NaN (undefined).
Arcutis Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | - | - | 891.89% | Buy |
| SPRO | Spero Therapeutics | - | - | 740.34% | Buy |
| CHRS | Coherus BioSciences | - | - | 718.18% | Hold |
| INZY | Inozyme Pharma | - | - | 445.35% | Buy |
| ABOS | Acumen Pharmaceuticals | - | - | 203.03% | Buy |
| ARQT | Arcutis Biotherapeutics | - | - | 202.73% | Buy |
| DAWN | Day One Biopharmaceuticals | - | - | 190.85% | Buy |
| APLS | Apellis Pharmaceuticals | - | - | 168.47% | Buy |
| ERAS | Erasca | - | - | 150.00% | Buy |
| TERN | Terns Pharmaceuticals | - | - | 149.56% | Buy |
| BOLT | Bolt Biotherapeutics | - | - | 75.44% | Hold |
| DSGN | Design Therapeutics | - | - | 73.61% | Buy |
| MIRM | Mirum Pharmaceuticals | - | - | 31.67% | Buy |
| AMLX | Amylyx Pharmaceuticals | - | - | 28.52% | Buy |
| VECT | VectivBio | - | - | 6.70% | Buy |
| GRCL | Gracell Bio | - | - | -41.46% | Buy |